InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.011

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Van Leeuwenhoeck Institute Updates Cynata Research Coverage 11 Oct 2017 9:43AM $0.630 $0.011 fallen by 98.25%
$3 Annual Report to Shareholders 9 Oct 2017 5:18PM $0.660 $0.011 fallen by 98.33%
$3 Notice of Annual General Meeting/Proxy Form 9 Oct 2017 5:16PM $0.660 $0.011 fallen by 98.33%
$3 Cynata to Increase Exposure in Japan 9 Oct 2017 9:51AM $0.645 $0.011 fallen by 98.29%
$3 US Patent Granted for Cynata Cymerus Technology 27 Sep 2017 11:03AM $0.655 $0.011 fallen by 98.32%
$3 HC Wainwright & Co Updates Cynata Research Coverage 11 Sep 2017 8:41AM $0.565 $0.011 fallen by 98.05%
$3 Cynata to Present at Rodman & Renshaw Investor Conference 5 Sep 2017 9:31AM $0.550 $0.011 fallen by 98%
$3 Health Canada Meeting Advances CYP Global Development Plans 31 Aug 2017 11:16AM $0.560 $0.011 fallen by 98.04%
$3 Appendix 4G 24 Aug 2017 6:45PM $0.580 $0.011 fallen by 98.10%
$3 Appendix 4E & Financial Statements 24 Aug 2017 6:44PM $0.580 $0.011 fallen by 98.10%
$3 Positive Data from CYP MSCs in 2nd Preclinical Asthma Study 23 Aug 2017 10:04AM $0.550 $0.011 fallen by 98%
$3 Appendix 3B 7 Aug 2017 6:18PM $0.590 $0.011 fallen by 98.14%
$3 June 2017 Quarterly Report 28 Jul 2017 4:50PM $0.630 $0.011 fallen by 98.25%
$3 NDF's Stuart Roberts Initiates Cynata Research Coverage 24 Jul 2017 12:31AM $0.600 $0.011 fallen by 98.17%
$3 FDA Meeting Provides Clear Path for US Development Plans 5 Jul 2017 9:24AM $0.600 $0.011 fallen by 98.17%
$3 Change of Address 4 Jul 2017 6:42PM $0.600 $0.011 fallen by 98.17%
$3 Cynata Therapeutics GvHD Clinical Trial & Corporate Progress 27 Jun 2017 10:01AM $0.645 $0.011 fallen by 98.29%
$3 CYP MSC Data in Asthma Model Published in Sceintific Journal 22 Jun 2017 12:35AM $0.635 $0.011 fallen by 98.27%
$3 Cynata Files New Patent Application for Cymerus in Oncology 20 Jun 2017 11:47AM $0.625 $0.011 fallen by 98.24%
$3 United States Patent for Core Cynata Technology 19 Jun 2017 1:24PM $0.625 $0.011 fallen by 98.24%
$3 Van Leeuwenhoeck Institute Initiates CYP Research Coverage 7 Jun 2017 9:19AM $0.570 $0.011 fallen by 98.07%
$3 Appendix 3Y-Peter Webse 2 Jun 2017 6:38PM $0.560 $0.011 fallen by 98.04%
$3 Appendix 3Y Lodged 26 May 2017-Date Correction 2 Jun 2017 6:38PM $0.560 $0.011 fallen by 98.04%
$3 Cynata Investor Presentation May 2017 29 May 2017 9:52AM $0.570 $0.011 fallen by 98.07%
$3 Appendix 3Y-Paul Wotton 26 May 2017 9:33AM $0.560 $0.011 fallen by 98.04%

551 - 575 of 699 results

Page 23 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.